Literature DB >> 28741147

Constipation in degenerative cervico-thoracic spine myelopathy: a simple co-existence or a complex inter-relationship?

Anant Mehrotra1, Janmejay Jamdar2, Pradeep Sharma2, Chaitanya Godbole2, Suyash Singh2, Kuntal Kanti Das2, Abhai Verma3, Kamlesh Singh Bhaisora2, Jayesh Sardhara2, Awadhesh Kumar Jaiswal2, Rabi Narayan Sahu2, Arun Kumar Srivastava2, Sanjay Behari2, Raj Kumar2.   

Abstract

PURPOSE: Identify factors affecting constipation and post surgical improvement in patients of myelopathy.
METHODS: Sixty-four patients with myelopathy due to extradural spine pathologies (47 cervical; 17 thoracic spine, male:female-5.4:1 with mean age 46.16) underwent evaluation including Bristol stool scale (BSS), PFT and uroflowmetry. All cases were evaluated by gastroenterologist to rule out any intrinsic bowel disease. Chi-square test, Kruskal-Wallis/Mann-Whitney U test and Wilcoxon signed rank test were employed to ascertain statistical significance.
RESULTS: The presence of constipation was associated with male sex (p = 0.01), degree of constipation with duration bladder symptoms (p = 0.008) and numbness (p = 0.04). The improvement in BSS after surgery (p = 0.006) was associated with local pain (p = 0.02), duration of weakness (p = 0.04) and overall symptoms (p = 0.01), also with pulmonary function tests (p = 0.002) and pre-operative Nurick's grade (p = 0.01).
CONCLUSION: Constipation is a myelopathic symptom as it is relieved by cord decompression and the gender, PFT and the duration of symptoms play an important role in defining constipation and expected improvement in these patients.

Entities:  

Keywords:  Bowel dysfunction; Constipation; Degenerative; Myelopathy; Non-traumatic spine pathologies; Urinary dysfunction

Mesh:

Year:  2017        PMID: 28741147     DOI: 10.1007/s00586-017-5227-z

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  10 in total

Review 1.  Challenging problems presenting as constipation.

Authors:  M E Stark
Journal:  Am J Gastroenterol       Date:  1999-03       Impact factor: 10.864

Review 2.  Constipation in neurological diseases.

Authors:  K Winge; D Rasmussen; L M Werdelin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

3.  Stool form scale as a useful guide to intestinal transit time.

Authors:  S J Lewis; K W Heaton
Journal:  Scand J Gastroenterol       Date:  1997-09       Impact factor: 2.423

4.  Morphological abnormalities of the recto-anal inhibitory reflex reflects symptom pattern in neurogenic bowel.

Authors:  Kumaran Thiruppathy; Amanda Roy; Giuseppe Preziosi; Jalesh Pannicker; Anton Emmanuel
Journal:  Dig Dis Sci       Date:  2012-03-18       Impact factor: 3.199

5.  How do patients with chronic spinal injury in Pakistan manage their bowels? A cross-sectional survey of 50 patients.

Authors:  R Yasmeen; F A Rathore; K Ashraf; A W Butt
Journal:  Spinal Cord       Date:  2010-05-04       Impact factor: 2.772

Review 6.  Gastrointestinal involvement in spinal cord injury: a clinical perspective.

Authors:  Ellen Ebert
Journal:  J Gastrointestin Liver Dis       Date:  2012-03       Impact factor: 2.008

7.  Gastrointestinal symptoms in spinal cord injury: relationships with level of injury and psychologic factors.

Authors:  Clinton Ng; Gillian Prott; Susan Rutkowski; Yueming Li; Ross Hansen; John Kellow; Allison Malcolm
Journal:  Dis Colon Rectum       Date:  2005-08       Impact factor: 4.585

8.  Intestinal transit in anxiety and depression.

Authors:  D A Gorard; J E Gomborone; G W Libby; M J Farthing
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

9.  Bowel dysfunction in spinal cord injury.

Authors:  A S Naicker; S A Roohi; M S Naicker; O Zaleha
Journal:  Med J Malaysia       Date:  2008-06

10.  How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form.

Authors:  K W Heaton; S Ghosh; F E Braddon
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.